FATE THERAPEUTICS INC (FATE) Stock Earnings & Estimates
NASDAQ:FATE - US31189P1021 - Common Stock
0.975 USD
-0.04 (-3.47%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 96.3M 72.43% | 63.533M -34.03% | 13.631M -78.55% | 7.038M -48.37% | 5.751M -18.29% | 6.854M 19.18% | 8.856M 29.21% | 86.254M 873.96% | 255.88M 196.66% | 331.54M 29.57% | 453.62M 36.82% | |
| EBITDA YoY % growth | -294.63M -39.54% | -172.229M 41.54% | -176.577M -2.52% | -178.429M -1.05% | -197.363M -10.61% | -282.848M -43.31% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -308.39M -42.12% | -190.511M 38.22% | -195.539M -2.64% | -153.85M 21.32% | -166.151M -8.00% | -198.26M -19.32% | -221.514M -11.73% | -181.469M 18.08% | -67.659M 62.72% | 72.42M 207.04% | 179.01M 147.18% | |
| Operating Margin | -320.24% | -299.86% | -1,434.52% | -2,185.99% | -2,889.08% | -2,892.62% | -2,501.29% | -210.39% | -26.44% | 21.84% | 39.46% | |
| EPS YoY % growth | -2.91 -30.49% | -1.64 43.64% | -1.64 | -1.17 28.54% | -1.12 4.26% | -0.87 22.77% | -0.91 -4.77% | -0.63 30.34% | -0.17 72.58% | 0.40 329.41% | 0.93 134.62% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 25.95% | -0.26 40.56% | -0.28 12.16% | -0.28 2.42% | -0.30 -2.17% | -0.28 -8.26% | -0.09 66.61% | -0.10 65.40% | -0.10 65.96% | -0.11 60.73% |
| Revenue Q2Q % growth | 1.569M -48.96% | 1.823M -1.99% | 1.107M -32.04% | 1.107M -41.95% | 1.158M -26.20% | 1.158M -36.48% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -33.742M 11.74% | -32.018M -14.15% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -36.944M 29.46% | -37.109M 21.06% | -41.444M -0.40% | -42.453M -14.84% | -41.804M -13.15% | -42.445M -14.38% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.29 12.12% | -0.35 | 0.06 | 16.98% |
| Q1 2025 Q2Q % growth | -0.32 31.91% | -0.39 | 0.07 | 18.09% |
| Q4 2024 Q2Q % growth | -0.44 2.22% | -0.44 | 0.00 | 0.25% |
| Q3 2024 Q2Q % growth | -0.40 13.04% | -0.44 | 0.04 | 9.28% |
| Q2 2024 Q2Q % growth | -0.33 38.89% | -0.48 | 0.15 | 31.92% |
| Q1 2024 Q2Q % growth | -0.47 -147.37% | -0.50 | 0.03 | 5.72% |
| Q4 2023 Q2Q % growth | -0.45 22.41% | -0.53 | 0.08 | 15.58% |
| Q3 2023 Q2Q % growth | -0.46 46.51% | -0.58 | 0.12 | 20.87% |
| Q2 2023 Q2Q % growth | -0.54 31.65% | -0.60 | 0.06 | 10.01% |
| Q1 2023 Q2Q % growth | -0.19 72.06% | -0.64 | 0.45 | 70.10% |
| Q4 2022 Q2Q % growth | -0.58 19.44% | -0.88 | 0.30 | 33.99% |
| Q3 2022 Q2Q % growth | -0.86 -91.11% | -0.91 | 0.05 | 5.60% |
| Q2 2022 Q2Q % growth | -0.79 -36.21% | -0.84 | 0.05 | 6.26% |
| Q1 2022 Q2Q % growth | -0.68 -41.67% | -0.78 | 0.10 | 12.89% |
| Q4 2021 Q2Q % growth | -0.72 -18.03% | -0.68 | -0.04 | -5.88% |
| Q3 2021 Q2Q % growth | -0.45 33.82% | -0.59 | 0.14 | 24.12% |
| Q2 2021 Q2Q % growth | -0.58 -65.71% | -0.54 | -0.04 | -7.83% |
| Q1 2021 Q2Q % growth | -0.48 -9.09% | -0.44 | -0.04 | -8.70% |
| Q4 2020 Q2Q % growth | -0.61 -64.86% | -0.40 | -0.21 | -52.15% |
| Q3 2020 Q2Q % growth | -0.68 -70.00% | -0.37 | -0.31 | -83.79% |
| Q2 2020 Q2Q % growth | -0.35 2.78% | -0.28 | -0.07 | -27.09% |
| Q1 2020 Q2Q % growth | -0.44 -46.67% | -0.40 | -0.04 | -10.86% |
| Q4 2019 Q2Q % growth | -0.37 | -0.39 | 0.02 | 5.96% |
| Q3 2019 Q2Q % growth | -0.40 | -0.38 | -0.02 | -4.08% |
| Q2 2019 Q2Q % growth | -0.36 | -0.33 | -0.03 | -7.82% |
| Q1 2019 Q2Q % growth | -0.30 | -0.24 | -0.06 | -22.99% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.907M -71.84% | 1.031M | 876K | 84.97% |
| Q1 2025 Q2Q % growth | 1.629M -15.38% | 1.165M | 464K | 39.83% |
| Q4 2024 Q2Q % growth | 1.86M 10.98% | 1.444M | 416K | 28.81% |
| Q3 2024 Q2Q % growth | 3.074M 58.13% | 1.352M | 1.722M | 127.37% |
| Q2 2024 Q2Q % growth | 6.772M 625.83% | 1.437M | 5.335M | 371.26% |
| Q1 2024 Q2Q % growth | 1.925M -96.74% | 1.137M | 788K | 69.31% |
| Q4 2023 Q2Q % growth | 1.676M -96.22% | 1.626M | 50K | 3.08% |
| Q3 2023 Q2Q % growth | 1.944M -87.02% | 912.329K | 1.032M | 113.08% |
| Q2 2023 Q2Q % growth | 933K -94.97% | 5.639M | -4.706M | -83.45% |
| Q1 2023 Q2Q % growth | 58.98M 220.37% | 36.213M | 22.767M | 62.87% |
| Q4 2022 Q2Q % growth | 44.36M 159.87% | 17.058M | 27.302M | 160.05% |
| Q3 2022 Q2Q % growth | 14.98M 5.27% | 15.939M | -959K | -6.02% |
| Q2 2022 Q2Q % growth | 18.55M 38.33% | 13.14M | 5.41M | 41.17% |
| Q1 2022 Q2Q % growth | 18.41M 65.26% | 9.585M | 8.825M | 92.07% |
| Q4 2021 Q2Q % growth | 17.07M 7.36% | 10.945M | 6.125M | 55.96% |
| Q3 2021 Q2Q % growth | 14.23M 88.23% | 8.047M | 6.183M | 76.84% |
| Q2 2021 Q2Q % growth | 13.41M 145.16% | 6.433M | 6.977M | 108.46% |
| Q1 2021 Q2Q % growth | 11.14M 342.06% | 6.02M | 5.12M | 85.05% |
| Q4 2020 Q2Q % growth | 15.9M 467.86% | 4.973M | 10.927M | 219.73% |
| Q3 2020 Q2Q % growth | 7.56M 211.11% | 7.111M | 449K | 6.31% |
| Q2 2020 Q2Q % growth | 5.47M 93.97% | 13.495M | -8.025M | -59.47% |
| Q1 2020 Q2Q % growth | 2.52M -4.18% | 1.826M | 694K | 38.01% |
| Q4 2019 Q2Q % growth | 2.8M | 1.832M | 968K | 52.84% |
| Q3 2019 Q2Q % growth | 2.43M | 1.829M | 601K | 32.86% |
| Q2 2019 Q2Q % growth | 2.82M | 1.187M | 1.633M | 137.57% |
| Q1 2019 Q2Q % growth | 2.63M | 2.423M | 207K | 8.54% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 13.66% | 35.66% | 14.33% | 19.44% |
| Revenue | 52.33% | 37.99% | 45.68% | 49.9% |